Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of
newly diagnosed glioblastoma (GBM). The objectives were to determine the efficacy of this
treatment combination and the associated toxicity. Patients and Methods Seventy patients
with newly diagnosed GBM were enrolled between August 2006 and November 2008.
Patients received standard RT starting within 3 to 6 weeks after surgery with concurrent …

Purpose This open-label, prospective, single-arm, phase II study combined erlotinib with
radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and
gliosarcoma. The objectives were to determine efficacy of this treatment as measured by
survival and to explore the relationship between molecular markers and treatment response.
Patients and Methods Sixty-five eligible adults with newly diagnosed GBM or gliosarcoma
were enrolled. We intended to treat patients not currently treated with enzyme-inducing …